http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_bb27732caaecaae0f730c65094c95a5e
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Aglietta |
| name | Massimo Aglietta |
| given-name | Massimo |
| organization-name | Sarcoma Unit, Division of Medical Oncology Candiolo Cancer Institute - FPO, IRCCS, Strada Provinciale, Candiolo, TO, Italy c Oncology Unit, University of Torino, Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy; Department of Oncology, University of Turin, Candiolo, Italy; Medical Oncology, Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy Division of Medical Oncology, Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy Division of Clinical Oncology University of Turin 10060 Candiolo Italy; Department of Oncological Sciences University of Turin 10060 Candiolo Italy a Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy From the Dipartimento di Genetica, Biologia e Chimica Medica, Dipartimento di Medicina Interna, and Dipartimento di Scienze Biomediche e Oncologia umana, Torino; Istituto di Ricerche Farmacologiche “Mario Negri,” Milano; and Sezione di Patologia Generale, Universita' di Brescia, Brescia, Italy. Department of Oncology, University of Torino, Turin, Italy; Division & Laboratory of Medical Oncology, Candiolo Cancer Institute FPO- IRCCS, Candiolo, Turin, Italy University Medical School of Turin, Turin, Italy Department of Medical Oncology Piemonte Oncology Foundation, IRCC‐Candiolo Candiolo Italy Department of Oncology University of Turin Medical School/Piedmont Foundation for Oncology, Candiolo Cancer Institute ‐ FPO, IRCCS Candiolo Italy Laboratory of Clinical Oncology, Department of Oncological Sciences, University of Torino Medical School, IRCC, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy Candiolo Cancer Institute FPO/IRCCS, Strada provinciale 142 km 3.95, 10060 Candiolo, Torino, Italy; Department of Oncology, University of Torino, Torino, Italy Candiolo Cancer Institute, FPO‐IRCCS Candiolo Turin Italy; Department of Oncology University of Turin Turin Italy Department of Medical Oncology, Candiolo Cancer Institute, University of Torino, Torino Department of Oncology, University of Turin, Turin, Italy; Division of Medical Oncology-1, Candiolo Cancer Institute-FPO- IRCCS, Candiolo, Italy Medical Oncology; Department of Oncology, University of Turin, Turin, Italy 1Department of Oncology, University of Turin, Turin, Italy.; 6Division of Medical Oncology—Experimental Cell Therapy, Candiolo Cancer Institute, FPO—IRCCS, Candiolo, Turin, Italy. 1Division of Medical Oncology, Experimental Cell Therapy, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.; 2Department of Oncology, University of Torino, Candiolo, Torino, Italy. Department of Medical Oncology, Fondazione del Piemonte per l'Oncologia, Candiolo Cancer Institute, Candiolo, Torino, Italy Department of Oncological Sciences, Laboratory of Clinical Oncology, University of Torino Medical School, Institute for Cancer Research and Treatment, IRCC Candiolo , Italy From the Department of Oncological Sciences, University of Torino Medical School, Torino, Italy; Laboratory Division of Clinical Oncology, Institute for Cancer Research and Treatment, Torino, Italy; and Laboratory of Gene Therapy, Institute for Cancer Research and Treatment, Torino, Italy. From the Department of Biomedical Sciences and Human Oncology, Clinical Section, Torino Medical School, University of Torino, Torino, Italy; the Torino Medical School, University of Torino, Hematology/Oncology, Ospedale Mauriziano, Torino, Italy; the Institute for Cancer Research and Treatment (IRCC), Candiolo, Italy; and the Department of Pediatrics, Torino, Italy. Department of Oncology, University of Turin, Turin, Italy; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy Candiolo Cancer Institute-FPO-IRCCS, Candiolo, Torino, Italy 1Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.; 2Department of Oncology, University of Torino, Turin, Italy. Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, University of Torino Medical School, 10060 Candiolo, Turin, Italy Division of Medical Oncology, Department of Oncological Sciences, Institute for Cancer Research and Treatment, Candiolo and University of Torino Medical School, Turin, Italy. Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy, Department of Oncology, University of Torino, Torino, Italy Medical Oncology I, Fondazione Del Piemonte Per l'Oncologia, IRCCS Candiolo, Turin, Italy Laboratory of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Italy Department of Oncology, University of Turin; Candiolo Cancer Institute - FPO- IRCCS, Candiolo, Italy Division of Medical Oncology, Candiolo Cancer Institute, FPO – IRCCS, Candiolo, TO, Italy; Department of Oncology, University of Turin, Torino, Italy Laboratory of Clinical Oncology, Department of Oncological Sciences, University of Torino Medical School, Institute for Cancer Research and Treatment, Candiolo (Torino) Italy Department of Oncology, University of Torino, Candiolo, Torino, Italy; Candiolo Cancer Institute, FPO-IRCCS Candiolo, Torino, Italy Department of Medical Oncology, Candiolo Cancer Institute, FPO‑IRCCS, I-10060 Candiolo, Italy Laboratory of Clinical Oncology, Institute for Cancer Research and Treatment, University of Turin Medical School, Candiolo, Italy; Division of Medical Oncology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy Department of Oncological Sciences, University of Torino Medical School, Candiolo, Torino, Italy; Division of Clinical Oncology, Institute for Cancer Research and Treatment, Candiolo, Torino, Italy Institute for Cancer Research and Treatment, Candiolo, Turin, Italy Medical Oncology, Candiolo Cancer Institute-FPO (IRCCS), Candiolo, Italy; Department of Oncology, University of Turin, Turin, Italy Department of Oncology, University of Turin, 10124 Torino, Italy; Division of Medical Oncology, Experimental Cell Therapy, Istituto di Candiolo, FPO- IRCCS, str. Prov.le 142 142, km 3.95, 10060 Candiolo, Italy Fondazione del Piemonte per l'Oncologia/Division of Medical Oncology I, Institute for Cancer Research and Treatment (IRCC), Torino, Italy Department of Oncology, University of Turin, Torino, Italy; Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy Medical Oncology, University of Turin, Oncology Network of Piemonte VdA, Candiolo Institute, FPO- IRCCS, 10060 Candiolo, Turin, Italy Authors' Affiliations: Units of 1Stem Cell Transplantation and Cell Therapy, 2Surgical Dermatology, 3Pathology, and 4Sarcoma, Fondazione del Piemonte per l'Oncologia, I.R.C.C.S.; 5Department of Oncology, University of Torino Medical School, Candiolo, Torino, Italy; Authors' Affiliations: Units of 1Stem Cell Transplantation and Cell Therapy, 2Surgical Dermatology, 3Pathology, and 4Sarcoma, Fondazione del Piemonte per l'Oncologia, I.R.C.C.S.; 5Department of Oncology, University of Torino Medical School, Candiolo, Torino, Italy Authors' Affiliations: 1Department of Medical Oncology, University of Turin Medical School; 2Unit of Molecular Pharmacology, Department of Oncological Sciences, University of Turin; 3Unit of Pathology, Fondazione del Piemonte per l'Oncologia; and 4Laboratory of Tumor Microenvironment, Fondazione Piemontese per la Ricerca sul Cancro, Institute for Cancer Research and Treatment (IRCC), Candiolo, Turin, Italy; Authors' Affiliations: 1Department of Medical Oncology, University of Turin Medical School; 2Unit of Molecular Pharmacology, Department of Oncological Sciences, University of Turin; 3Unit of Pathology, Fondazione del Piemonte per l'Oncologia; and 4Laboratory of Tumor Microenvironment, Fondazione Piemontese per la Ricerca sul Cancro, Institute for Cancer Research and Treatment (IRCC), Candiolo, Turin, Italy a Division of Medical Oncology, Fondazione del Piemonte per l'Oncologia/Institute for Cancer Research and Treatment, Candiolo, Italy Istituto di Candiolo IRCC, Candiolo Torin, Italy Authors' Affiliations: 1Stem Cell Transplantation and Cell Therapy, 2Pathology, 3Sarcoma, Fondazione del Piemonte per l'Oncologia, 4Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment; 5Department of Oncology, University of Torino Medical School; and 6Division of Pediatric Onco-Hematology, Sant'Anna OIRM Hospital, (Torino), Italy; Authors' Affiliations: 1Stem Cell Transplantation and Cell Therapy, 2Pathology, 3Sarcoma, Fondazione del Piemonte per l'Oncologia, 4Laboratory of Molecular Pharmacology, Institute for Cancer Research and Treatment; 5Department of Oncology, University of Torino Medical School; and 6Division of Pediatric Onco-Hematology, Sant'Anna OIRM Hospital, (Torino), Italy Cattedra di Oncologia Medica, Università di Torino; Division of Medical Oncology, Institute for Cancer Research and Treatment, Torino, Italy (Istituto di Medicina Interna dell'Università, 1 Cattedra di Patologia Speciale Medica, Torino) Medical Oncology, Candiolo Cancer Institute, Fondazione del Piemonte per l'Oncologia (FPO)-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Torino, Italy Department of Oncology, University of Turin, Candiolo, Italy; Department of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy Rete Oncologica del Piemonte e della Valle d'Aosta A.O.U. City of Health and Science of Turin Turin Italy; Department of Oncology University of Turin Turin Italy; Candiolo Cancer Institute FPO‐IRCCS Candiolo TO Italy Department of Oncology University of Turin Turin Italy; Candiolo Cancer Institute, FPO‐IRCCS Candiolo Italy Medical Oncology Division, Candiolo Cancer Institute, FPO–IRCCS. Str. Prov. 142, km 3.95, I-10060, Candiolo (To), Italy; Department of Oncology, University of Torino, Candiolo (Torino) Italy Medical Oncology, Institute for Cancer Research and Treatment IRCC, Candiolo, Turin, Italy Medical Oncology I; Institute for Cancer Research and Treatment (IRCC) FPO (Fondazione del Piemonte per l'Oncologia); Candiolo Italy; Department of Oncology; University of Torino Medical School; Candiolo Italy Division of Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy; Department of Oncology, University of Torino, Torino, Italy Istituto di Candiolo, Fondazione del Piemonte per l’Oncologia, IRCCS, Candiolo, Italy; Dipartimento di Oncologia, Università degli Studi di Torino, Turin, Italy Medical Oncology Division, Fondazione del Piemonte per l'Oncologia (FPO), Candiolo Cancer Institute IRCCS, Candiolo, Italy; Department of Oncology, University of Turin, Candiolo Cancer Institute IRCCS, Candiolo, Italy University of Turin Medical School, Department of Oncology, IRCCS-Institute Candiolo, Italy; Medical Oncology Division, Fondazione del Piemonte per l’Oncologia (FPO), IRCCS-Institute Candiolo, Italy From the Dipartimento di Scienze Mediche, Dipartimento di Scienze Biomediche ed Oncologia Umana, Dipartimento di Anatomia, Farmacologia e Medicina Legale and Dipartimento di Scienze Biomediche ed Oncologia Umana and Divisione Universitaria di Ematologia ed Oncologia, Università di Torino, Torino, Italy; and Amgen Inc, Thousand Oaks, CA. Department of Oncology University of Turin Medical School IRCCS‐Candiolo Turin Italy; Fondazione del Piemonte per l'Oncologia (FPO) IRCCS‐Candiolo Turin Italy Department of Oncology, University of Torino, Candiolo, Torino, Italy; Division of Medical Oncology, Experimental Cell Therapy, Candiolo Cancer Institute, Candiolo, Torino, Italy Michael J. Overman and Scott Kopetz, University of Texas MD Anderson Cancer Center, Houston, TX; Sara Lonardi, Istituto Oncologico Veneto, Istituto di Ricovero e Cura a Carattere Scientifico, Padova; Fabio Gelsomino, University Hospital of Modena, Modena; Massimo Aglietta, Institute for Cancer Research and Treatment of Candiolo, University of Torino Medical School, Turin, Italy; Ka Yeung Mark Wong, Sydney Medical School, University of Sydney, Sydney, New South Wales; Andrew Hill, Tasman Oncology Research... Medical Oncology Candiolo Cancer Institute‐FPO, IRCCS Candiolo Italy; Department of Medical Oncology University of Turin Turin Italy 1Clinical Oncology and Department of Oncological Sciences and Laboratories of Department of Medical Oncology Candiolo Cancer Institute–FPO IRCCS Torino Italy a Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment, Division of Medical Oncology I, Candiolo, Italy Istituto per la Ricerca e la Cura del Cancro, Candiolo, Torino, Italy From the Department of Biomedical Sciences and Human Oncology, University of Torino Medical School, Torino; the Hematology/Oncology Section, Mauriziano Hospital, Torino; the Pediatric Department; the Institute for Cancer Research and Treatment (IRCC), Candiolo, Torino, Italy; and the Department of Immunology, the Weizmann Institute of Science, Rehovot, Israel. From the Laboratory of Clinical Oncology, IRCC—Institute for Cancer Research and Treatment, Torino, Italy; James Ewing Laboratory of Developmental Hematopoiesis, Memorial Sloan-Kettering Cancer Center, New York, NY; and Department of Clinical Sciences, Section of Hemato-Oncology, University of Parma Medical School, Parma, Italy. Department of Oncology, University of Turin Medical School, Turin, Italy; Medical Oncology, Candiolo Cancer Institute – FPO- IRCCS, Candiolo, Italy Department of Oncology, Candiolo Cancer Center, University of Torino, Torino Department of Biomedical Sciences and Oncology, University of Turin Medical School, 10126 Turin, Italy Department of Oncology, University of Turin, Torino, Italy; Division of Medical Oncology, Candiolo Cancer Institute, FPO – IRCCS, Candiolo, Italy Department of Medical Oncology, University of Torino, FPO-IRCCS, Candiolo, Italy 1Clinical Oncology, Departments of University Division of Medical Oncology and Hematology, Institute for Cancer Research and Treatment, Torino, Italy Division of Oncology, IRCC, Candiolo, Italy; and Clinical Medicine A, Department of Science, Biomedicine and Oncology, University of Torino, Italy Authors' Affiliations: 1Sarcoma Group, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 2Department of Oncology, University of Torino Medical School, 3Tumor Microenvironment, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 4Department of Internal Medicine, University of Torino, Molecular Biotechnology Center and Center of Experimental Research and Medical Sciences, Torino, Italy; 5Cell Therapy, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 6Cancer Genetics, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 7Division of Pediatric Onco-Hematology, Sant'Anna OIRM Hospital, Torino, Italy; 8Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy; 9Medical Oncology, Fondazione del Piemonte per ÍOncologia, Institute for; Authors' Affiliations: 1Sarcoma Group, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 2Department of Oncology, University of Torino Medical School, 3Tumor Microenvironment, Fondazione Piemontese per la Ricerca sul Cancro-ONLUS, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 4Department of Internal Medicine, University of Torino, Molecular Biotechnology Center and Center of Experimental Research and Medical Sciences, Torino, Italy; 5Cell Therapy, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 6Cancer Genetics, Fondazione del Piemonte per l'Oncologia, Institute for Cancer Research and Treatment at Candiolo, Torino, Italy; 7Division of Pediatric Onco-Hematology, Sant'Anna OIRM Hospital, Torino, Italy; 8Department of Musculoskeletal Oncology, Istituti Ortopedici Rizzoli, Bologna, Italy; 9Medical Oncology, Fondazione del Piemonte per ÍOncologia, Institute for |
Incoming Links
Total number of triples: 367.